• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶瘤呼肠孤病毒(pelareorep)诱导 KRAS 突变型结直肠癌发生自噬。

Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer.

机构信息

Albert Einstein College of Medicine, Bronx, New York.

Montefiore Medical Center, Bronx, New York.

出版信息

Clin Cancer Res. 2021 Feb 1;27(3):865-876. doi: 10.1158/1078-0432.CCR-20-2385. Epub 2020 Nov 9.

DOI:10.1158/1078-0432.CCR-20-2385
PMID:33168658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8130598/
Abstract

PURPOSE

To explore the effects of pelareorep on autophagy in multiple models of colorectal cancer, including patient-derived peripheral blood mononuclear cells (PBMCs).

EXPERIMENTAL DESIGN

HCT116 [KRAS mutant (mut)] and Hke3 [ wild-type (WT)] cells were treated with pelareorep (multiplicity of infection, 5) and harvested at 6 and 9 hours. LC3 A/B expression was determined by immunofluorescence and flow cytometry; five autophagic proteins were analyzed by Western blotting. The expression of 88 autophagy genes was determined by qRT-PCR. Syngeneic mouse models, CT26/Balb-C ( mut) and MC38/C57B6 ( WT), were developed and treated with pelareorep (10 × 10 plaque-forming unit/day) intraperitoneally. Protein and RNA were extracted from harvested tumor tissues. PBMCs from five experimental and three control patients were sampled at 0 (pre) and 48 hours, and on days 8 and 15. The gene expression normalized to "pre" was determined using 2 method.

RESULTS

Pelareorep induced significant upregulation of LC3 A/B in HCT116 as compared with Hke3 cells by immunofluorescence (3.24 × and 8.67 ×), flow cytometry (2.37 × and 2.58 ×), and autophagosome formation (2.02 × and 1.57 ×), at 6 and 9 hours, respectively; all < 0.05. Western blot analysis showed an increase in LC3 A/B (2.38 × and 6.82 ×) and Beclin1 (1.17 × and 1.24 ×) at 6 and 9 hours, ATG5 (2.4 ×) and P-62 (1.52 ×) at 6 hours, and VPS-34 (1.39 ×) at 9 hours (all < 0.05). Induction of 13 transcripts in cell lines (>4 ×; 6 and 9 hours; < 0.05), 12 transcripts in CT26 (qRT-PCR), and 14 transcripts in human PBMCs ( < 0.05) was observed. , and expression was upregulated in all three model systems.

CONCLUSIONS

Pelareorep hijacks host autophagic machinery in -mut conditions to augment its propagation and preferential oncolysis of the cancer cells.

摘要

目的

探索 pelareorep 在包括源自患者外周血单核细胞(PBMC)的结直肠癌多种模型中的自噬作用。

实验设计

用 pelareorep(感染复数,5)处理 HCT116[KRAS 突变(mut)]和 Hke3[野生型(WT)]细胞,并在 6 小时和 9 小时收获细胞。通过免疫荧光和流式细胞术测定 LC3 A/B 的表达;通过 Western blot 分析 5 种自噬蛋白。通过 qRT-PCR 测定 88 种自噬基因的表达。建立并经 pelareorep(10×10 噬菌斑形成单位/天)腹腔内给药的同基因小鼠模型 CT26/Balb-C(mut)和 MC38/C57B6(WT)。从收获的肿瘤组织中提取蛋白质和 RNA。在 0(预处理)和 48 小时以及第 8 天和第 15 天,从 5 名实验患者和 3 名对照患者中采集 PBMC。使用 2-∆∆CT 方法确定相对于“预处理”的基因表达。

结果

与 Hke3 细胞相比,pelareorep 在 HCT116 中诱导 LC3 A/B 的免疫荧光(3.24×和 8.67×)、流式细胞术(2.37×和 2.58×)和自噬体形成(2.02×和 1.57×)分别显著上调,均 < 0.05。Western blot 分析显示 LC3 A/B(2.38×和 6.82×)和 Beclin1(1.17×和 1.24×)在 6 小时和 9 小时、ATG5(2.4×)和 P-62(1.52×)在 6 小时以及 VPS-34(1.39×)在 9 小时增加(均 < 0.05)。在细胞系中观察到 13 个转录物的诱导(>4×;6 小时和 9 小时;均 < 0.05)、CT26 中的 12 个转录物(qRT-PCR)和人 PBMCs 中的 14 个转录物(均 < 0.05)。在所有三个模型系统中, 、 和 的表达均上调。

结论

Pelareorep 在 -mut 条件下劫持宿主自噬机制,以增强其增殖和对癌细胞的优先溶瘤作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/44a59a46e5b2/nihms-1645732-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/d5ad7d456f7b/nihms-1645732-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/b4e3a301f7af/nihms-1645732-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/30d788f73965/nihms-1645732-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/464b19cd48a2/nihms-1645732-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/f2ad070cdcba/nihms-1645732-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/294bd669e9ee/nihms-1645732-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/4f0a22f85a11/nihms-1645732-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/bdf437d8062a/nihms-1645732-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/44a59a46e5b2/nihms-1645732-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/d5ad7d456f7b/nihms-1645732-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/b4e3a301f7af/nihms-1645732-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/30d788f73965/nihms-1645732-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/464b19cd48a2/nihms-1645732-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/f2ad070cdcba/nihms-1645732-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/294bd669e9ee/nihms-1645732-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/4f0a22f85a11/nihms-1645732-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/bdf437d8062a/nihms-1645732-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ad4/8130598/44a59a46e5b2/nihms-1645732-f0010.jpg

相似文献

1
Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer.溶瘤呼肠孤病毒(pelareorep)诱导 KRAS 突变型结直肠癌发生自噬。
Clin Cancer Res. 2021 Feb 1;27(3):865-876. doi: 10.1158/1078-0432.CCR-20-2385. Epub 2020 Nov 9.
2
Immune characterization of metastatic colorectal cancer patients post reovirus administration.经病毒治疗的转移性结直肠癌患者的免疫特征。
BMC Cancer. 2020 Jun 18;20(1):569. doi: 10.1186/s12885-020-07038-2.
3
Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.溶瘤呼肠孤病毒优先诱导KRAS突变型结肠癌细胞凋亡,并与伊立替康协同作用。
Oncotarget. 2014 May 15;5(9):2807-19. doi: 10.18632/oncotarget.1921.
4
Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with -Mutated Colorectal Cancer.阐明在 - 突变型结直肠癌患者中进行的 I 期试验中的 Pelareorep 的药效动力学。
Mol Cancer Ther. 2020 May;19(5):1148-1156. doi: 10.1158/1535-7163.MCT-19-1117. Epub 2020 Mar 10.
5
A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.一项 FOLFOX6/贝伐珠单抗联合或不联合培拉利奥雷普治疗转移性结直肠癌患者的随机 II 期研究:IND.210,一项加拿大癌症临床试验组的研究。
Clin Colorectal Cancer. 2018 Sep;17(3):231-239.e7. doi: 10.1016/j.clcc.2018.03.001. Epub 2018 Mar 8.
6
Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.预测和预后意义的 4E-BP1、Beclin-1 和 LC3 西妥昔单抗联合化疗治疗野生型 KRAS 晚期结直肠癌的:来自真实世界数据的分析。
World J Gastroenterol. 2019 Apr 21;25(15):1840-1853. doi: 10.3748/wjg.v25.i15.1840.
7
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.派姆单抗联合溶瘤病毒 Pelareorep 和化疗治疗晚期胰腺腺癌患者的 Ib 期研究。
Clin Cancer Res. 2020 Jan 1;26(1):71-81. doi: 10.1158/1078-0432.CCR-19-2078. Epub 2019 Nov 6.
8
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.一项比较帕尼单抗联合氟尿嘧啶、亚叶酸钙和伊立替康(FOLFIRI)与单独 FOLFIRI 二线治疗转移性结直肠癌患者的随机 III 期研究。
J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.
9
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.检测外周血中KRAS癌基因作为转移性结直肠癌患者对西妥昔单抗联合化疗反应的预测指标。
Clin Cancer Res. 2009 Jul 1;15(13):4508-13. doi: 10.1158/1078-0432.CCR-08-3179. Epub 2009 Jun 23.
10
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.晚期结直肠癌中的KRAS和BRAF突变与预后不良相关,但不排除从奥沙利铂或伊立替康治疗中获益:MRC FOCUS试验结果
J Clin Oncol. 2009 Dec 10;27(35):5931-7. doi: 10.1200/JCO.2009.22.4295. Epub 2009 Nov 2.

引用本文的文献

1
Immunotherapy in Gastrointestinal Cancers: Current Insights.胃肠道癌症的免疫疗法:当前见解
Clin Pharmacol. 2025 Jul 23;17:167-183. doi: 10.2147/CPAA.S497836. eCollection 2025.
2
Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer.泛RAS抑制剂与 polo样激酶1:结直肠癌中有前景的靶点
Oncogene. 2025 Aug;44(30):2565-2573. doi: 10.1038/s41388-025-03484-z. Epub 2025 Jul 4.
3
Modulating autophagy in KRAS mutant colorectal cancer using combination of oncolytic reovirus and carbamazepine.使用溶瘤呼肠孤病毒和卡马西平联合疗法调节KRAS突变型结直肠癌中的自噬

本文引用的文献

1
Immune characterization of metastatic colorectal cancer patients post reovirus administration.经病毒治疗的转移性结直肠癌患者的免疫特征。
BMC Cancer. 2020 Jun 18;20(1):569. doi: 10.1186/s12885-020-07038-2.
2
Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with -Mutated Colorectal Cancer.阐明在 - 突变型结直肠癌患者中进行的 I 期试验中的 Pelareorep 的药效动力学。
Mol Cancer Ther. 2020 May;19(5):1148-1156. doi: 10.1158/1535-7163.MCT-19-1117. Epub 2020 Mar 10.
3
Autophagy-Virus Interplay: From Cell Biology to Human Disease.
PLoS One. 2025 Jun 17;20(6):e0326029. doi: 10.1371/journal.pone.0326029. eCollection 2025.
4
Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment (Review).结直肠癌的精准溶瘤病毒疗法:用于个性化治疗的基因靶向和免疫调节(综述)
Int J Mol Med. 2025 Jul;56(1). doi: 10.3892/ijmm.2025.5545. Epub 2025 May 9.
5
Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches.结直肠癌治疗的新兴前沿领域:从靶向分子到免疫调节突破及基于细胞的方法。
Dig Dis Sci. 2025 Mar;70(3):919-942. doi: 10.1007/s10620-024-08774-2. Epub 2025 Jan 27.
6
Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies.结直肠癌的分子复杂性:途径、生物标志物和治疗策略。
Cancer Manag Res. 2024 Oct 10;16:1389-1403. doi: 10.2147/CMAR.S481656. eCollection 2024.
7
Exploring treatment options in cancer: Tumor treatment strategies.探索癌症的治疗选择:肿瘤治疗策略。
Signal Transduct Target Ther. 2024 Jul 17;9(1):175. doi: 10.1038/s41392-024-01856-7.
8
Human Umbilical Cord-Derived Mesenchymal Stem Cells-Exosomes-Delivered miR-375 Targets HDAC4 to Promote Autophagy and Suppress T Cell Apoptosis in Sepsis-Associated Acute Kidney Injury.人脐带间充质干细胞来源的外泌体递送的miR-375靶向HDAC4以促进自噬并抑制脓毒症相关性急性肾损伤中的T细胞凋亡。
Appl Biochem Biotechnol. 2024 Nov;196(11):7954-7973. doi: 10.1007/s12010-024-04963-x. Epub 2024 Apr 26.
9
Immune landscape and response to oncolytic virus-based immunotherapy.免疫景观与基于溶瘤病毒免疫治疗的反应
Front Med. 2024 Jun;18(3):411-429. doi: 10.1007/s11684-023-1048-0. Epub 2024 Mar 8.
10
Oncolytic Increases Autophagy in Multiple Myeloma.溶瘤病毒增加多发性骨髓瘤中的自噬。
Turk J Haematol. 2024 Mar 1;41(1):16-25. doi: 10.4274/tjh.galenos.2024.2023.0403. Epub 2024 Jan 23.
自噬与病毒的相互作用:从细胞生物学到人类疾病
Front Cell Dev Biol. 2018 Nov 19;6:155. doi: 10.3389/fcell.2018.00155. eCollection 2018.
4
STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.STRING v11:具有增强覆盖范围的蛋白质-蛋白质相互作用网络,支持在全基因组实验数据集的功能发现。
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613. doi: 10.1093/nar/gky1131.
5
Exploring the Role of Autophagy-Related Gene 5 () Yields Important Insights Into Autophagy in Autoimmune/Autoinflammatory Diseases.探讨自噬相关基因 5() 在自身免疫/自身炎症性疾病中的自噬作用
Front Immunol. 2018 Oct 17;9:2334. doi: 10.3389/fimmu.2018.02334. eCollection 2018.
6
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer.同时靶向mTOR/MAPK通路:在特定改变的非小细胞肺癌亚组中的新型治疗策略
Oncotarget. 2018 Sep 21;9(74):33995-34008. doi: 10.18632/oncotarget.26129.
7
Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy.自噬在癌症中的调控:作用与治疗的现有知识。
Oxid Med Cell Longev. 2018 Jan 31;2018:8023821. doi: 10.1155/2018/8023821. eCollection 2018.
8
Autophagy during viral infection - a double-edged sword.病毒感染期间的自噬作用——一把双刃剑。
Nat Rev Microbiol. 2018 Jun;16(6):341-354. doi: 10.1038/s41579-018-0003-6.
9
The role of RICTOR downstream of receptor tyrosine kinase in cancers.受体酪氨酸激酶下游 RICTOR 在癌症中的作用。
Mol Cancer. 2018 Feb 19;17(1):39. doi: 10.1186/s12943-018-0794-0.
10
mTOR Pathways in Cancer and Autophagy.癌症与自噬中的mTOR信号通路
Cancers (Basel). 2018 Jan 12;10(1):18. doi: 10.3390/cancers10010018.